West Virginia
Requires Coverage of Comprehensive Biomarker Testing
No
Highlighted Disparity
No racial disparities were found in West Virginia for these lung cancer metrics
Lung Cancer Rates
New Cases:
- The rate of new lung cancer cases in West Virginia is 75.9 and significantly higher than the national rate of 52.1.
- It ranks 50th among all states, placing it in the bottom tier.
- Over the last five years, the rate of new cases in West Virginia did not change significantly.
- Note: When examining incidence data, it is important to note that the COVID-19 pandemic disrupted access to medical care. This resulted in a drop in cancer diagnoses for the year 2020, particularly for cancers diagnosed before symptoms develop (including lung cancer). This drop reflects changes in medical care for 2020 and should not necessarily be interpreted as a reduction in the underlying cancer burden.
Five-Year Survival Rate:
- The percent of people living five years after being diagnosed with lung cancer (the survival rate) in West Virginia is 26.4%, which is significantly lower than the national rate of 31.0%.
- It ranks 37th among the 43 states with survival data, placing it in the bottom tier.
- Over the last five years, the survival rate in West Virginia improved by 29%.
Early Diagnosis:
- In West Virginia, 29.2% of cases are caught at an early stage, which is not significantly different than the national rate of 29.3%.
- It ranks 29th among the 47 states with data on diagnosis at an early stage, placing it in the average tier.
- Over the last five years, the early diagnosis rate in West Virginia improved by 19%.
Lung Cancer Treatment
Biomarker Coverage:
- West Virginia has yet to require any insurance coverage of comprehensive biomarker testing, including for lung cancer, as of September 2026.
Surgical Treatment:
- West Virginia ranked 18th (out of the 40 states with available data) with 20.8% of cases undergoing surgery as part of the first course of treatment.
- This is not significantly different than the national rate of 21.4% and puts West Virginia in the average tier.
No Treatment:
- West Virginia ranked 36th (out of the 47 states with available data) with 23.7% of cases not receiving any treatment.
- This is significantly higher than the national rate of 20.9% and puts West Virginia in the average tier.
Screening
Screening for High Risk:
- In West Virginia, 26.4% of those at high risk were screened, which was not significantly different than the national rate of 24.4%.
- It ranks 13th (out of the 50 states with available data), placing it in the average tier.
Prevention
Tobacco Use:
- The 2025 smoking rate in West Virginia is 17.8% and significantly higher than the national rate of 10.4%.
- It ranks 48th (out of the 48 states with available data), placing it in the bottom tier.
Radon:
- In West Virginia, 28.5% of radon tests results were at or above the action level recommended by EPA.
- It ranks 31st among all states, placing it in the average tier.
Racial & Ethnic Disparities
Black individuals:
- The rate of new lung cancer cases is 61.3 per 100,000 population among Black individuals in West Virginia, not significantly different than the rate of 53.5 among Black individuals nationally, and significantly lower than the rate of 77.3 among white individuals in West Virginia.
- The five-year survival rate is 28.9% among Black individuals in West Virginia, not significantly different than the rate of 28.5% among Black individuals nationally, and not significantly different than the rate of 26.2% among white individuals in West Virginia.
31.1% of lung cancer cases are diagnosed at an early stage among Black individuals in West Virginia, not significantly different than the rate of 26.3% among Black individuals nationally, and not significantly different than the rate of 29.2% among white individuals in West Virginia.
20.2% of Black individuals with lung cancer in West Virginia underwent surgery, not significantly different than the rate of 17.9% among Black individuals nationally, and not significantly different than the rate of 20.8% among white individuals in West Virginia.
21.4% of Black individuals with lung cancer in West Virginia did not receive any treatment, not significantly different than the rate of 22.7% among Black individuals nationally, and not significantly different than the rate of 23.8% among white individuals in West Virginia.
Latino individuals:
- Lung cancer data (including rates, early diagnosis, surgery, lack of treatment) is incomplete or unavailable for Latino individuals in West Virginia due to data limitations.
Asian or Pacific Islander individuals:
- The rate of new lung cancer cases is 28.7 per 100,000 population among Asian or Pacific Islanders individuals in West Virginia, not significantly different than the rate of 32.7 among Asian or Pacific Islanders individuals nationally, and significantly lower than the rate of 77.3 among white individuals in West Virginia.
- State-level survival rates are not available for Asian or Pacific Islander individuals at this time. Nationally, the five-year survival rate among Asian or Pacific Islander individuals is 28.6% and significantly higher than the rate of 25.0% among white individuals.
Lung cancer data (including early diagnosis, surgery, lack of treatment) is incomplete or unavailable for Asian or Pacific Islander individuals in West Virginia due to data limitations.
Indigenous Peoples:
- Lung cancer data (including rates, early diagnosis, surgery, lack of treatment) is incomplete or unavailable for Indigenous Peoples (American Indians/Alaska Natives) in West Virginia due to data limitations.
Summary
Despite the early diagnosis rate in West Virginia falling into the average tier, the state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.
West Virginia has yet to require any insurance coverage of comprehensive biomarker testing, which can help determine what treatment options would be best for individuals with lung cancer and other diseases.
West Virginia falls into the average tier for percent of patients receiving no treatment. Some patients do refuse treatment, but issues such as fatalism and stigma can prevent eligible patients from accessing treatment that may save or extend their lives. All patients should work with their doctors to establish a treatment plan and goals.
Page last updated: November 10, 2026